Our Story

Be Informed. Be Smart. Be Sure.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean feugiat dictum lacus, ut hendrerit mi pulvinar vel. Fusce id nibh at neque eleifend tristique at sit amet libero. In aliquam in nisl nec sollicitudin. Sed consectetur volutpat sem vitae facilisis. Fusce tristique, magna ornare facilisis sagittis, tortor mi auctor libero, non pharetra sem ex eu felis. Aenean egestas ut purus nec vehicula. Morbi eu nisi erat. Nam mattis id lectus sit amet mattis. Suspendisse eget tristique neque

Working Hours

Monday - Friday 09:00AM-17:00PM
Saturday - Sunday CLOSED

Latest News

    No posts were found.


Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

Quark VentureNews Release Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022


NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry.

“It is an honor and tremendous validation of our team and progress to be among the Fierce 15,” said Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra. “Our unique understanding of chromosomal instability combined with our proprietary CINtech platform allows us to develop potentially life-saving therapies for patients. I am extremely proud of what we have accomplished in just the last three years, and the promise of what lies ahead.”

Michael Su, Ph.D., the company’s Chief Scientific Officer, added, “We are particularly excited about our lead program, a KIF18A inhibitor that is on track to begin a Phase 1 trial in the second half of 2023. We recently announced compelling preclinical data supporting the potential of Volastra’s KIF18A inhibitor to induce tumor regression.”

Now in its 20th Fierce 15 selection, Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual list, which celebrates the spirit of being “fierce”— championing innovation and creativity in the face of strong competition. Winners are selected based on a variety of factors, such as the strength of their scientific approach, leadership, technology, partnerships, venture backers, and scale of unmet needs they are solving for.

About Fierce Biotech

Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news, and more. More than 450,000 top biopharma professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com.

About Volastra Therapeutics, Inc.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), a key vulnerability of cancer. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune-activating pipeline. Volastra’s lead program targets KIF18A, a mitotic kinesin, with a first-in-human study anticipated to start in 2023. Volastra recently announced a multi-year, up to $1.1 billion drug discovery collaboration with Bristol Myers Squibb leveraging Volastra’s proprietary CINtech platform to identify CIN-related targets. In addition, Volastra has a partnership with Microsoft to develop AI technologies for the high-throughput interrogation of CIN.

For more information, please visit volastratx.com.


Lisa Qu

Quark Venture
No Comments

Sorry, the comment form is closed at this time.